Production (Stage)
Yubo International Biotech Limited
YBGJ
$0.0612
$0.015233.04%
OTC PK
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -100.00% | -99.43% | -96.05% | 90.00% | 85.47% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -100.00% | -99.43% | -96.05% | 90.00% | 85.47% |
| Cost of Revenue | 135.71% | 13.14% | -0.09% | 53.03% | -37.40% |
| Gross Profit | -157.93% | -149.71% | -145.27% | 144.08% | 258.28% |
| SG&A Expenses | 20.32% | 11.83% | 142.05% | 142.13% | 49.61% |
| Depreciation & Amortization | -20.09% | -3.58% | 196.30% | 468.39% | 618.35% |
| Other Operating Expenses | -2.45% | 9.55% | -1.23% | -21.06% | 14.85% |
| Total Operating Expenses | 17.00% | 9.96% | 76.74% | 86.18% | 46.43% |
| Operating Income | -58.41% | -65.61% | -272.65% | -85.06% | -36.28% |
| Income Before Tax | -58.37% | -65.83% | -273.85% | -85.57% | -36.60% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -58.37% | -65.83% | -273.85% | -85.57% | -36.60% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 539.44% | -- | -- | -- | -- |
| Net Income | -46.02% | -48.55% | -248.89% | -72.99% | -33.19% |
| EBIT | -58.41% | -65.61% | -272.65% | -85.06% | -36.28% |
| EBITDA | -75.20% | -78.64% | -286.07% | -62.87% | -16.14% |
| EPS Basic | 60.82% | -335.35% | -857.45% | -489.71% | -391.14% |
| Normalized Basic EPS | 61.80% | -303.17% | -764.52% | -443.18% | -356.86% |
| EPS Diluted | 60.82% | -335.35% | -857.45% | -489.71% | -391.14% |
| Normalized Diluted EPS | 61.80% | -303.17% | -764.52% | -443.18% | -356.86% |
| Average Basic Shares Outstanding | 29.03% | -22.50% | -22.50% | -22.32% | -22.05% |
| Average Diluted Shares Outstanding | 29.03% | -22.50% | -22.50% | -22.32% | -22.05% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |